Introduction
VNS is an effective adjunctive therapy for patients with drugresistant partial onset epilepsy. 1 It decreases seizure frequency by approximately 50% in 30-40% of implanted patients. 2 The efficacy of VNS has also been demonstrated in treating various types of generalized epilepsies, including genetic generalized epilepsy (GGE) and Lennox-Gastaut syndrome. 3 Although VNS is primarily a palliative treatment, seizure freedom has been reported in a small percentage of patients. However, AEDs are commonly required to maintain seizure freedom. Here we report that a patient became seizure free with VNS monotherapy.
Case report
A 37-year-old, right-handed man started having seizures at age of 18. He reports monthly brief staring spells lasting for a few seconds, and occasional generalized tonic clonic seizures at a frequency of 4-5 times per year. His seizures are commonly precipitated by stress, sleep deprivation and AED noncompliance. He was initially treated with phenytoin (PTN) and carbamazepine (CBM) with minimal benefits. He was also treated with valproic acid (VPA), which provided better seizure control, but it had to be discontinued due to significant fatigue, gastrointestinal discomfort and cognitive impairments. He has been treated with lamotrigine (LTG) 400 mg daily and gabapentin (GBP) 1800 mg daily for the last several years.
His general physical and neurological examinations were normal, as were his brain MRI and routine EEG. His family history was noncontributory and past medical history was significant for HIV diagnosed at age of 28. His HIV infection has been well controlled with medications and his viral counts have remained undetectable. Although he has never had systemic infections secondary to HIV, he has been debilitated by fatigue and drowsiness due to the adverse effects of his medications, which has prevented him from working. He was referred by his neurologist to our epilepsy center for evaluation for possible VNS therapy.
Long-term video-EEG monitoring revealed 3-4 Hz generalized spike-wave discharges (GSW) (Fig. 1) . After complete withdrawal of AEDs, the GSW became more frequent and were of longer duration. One generalized tonic clonic seizure (GTC) was recorded (Fig. 2) . These EEG findings were consistent with IGE, likely juvenile absence epilepsy. A vagus nerve stimulator was subsequently implanted in 2006. Final stimulation parameters were: current output 1.75 mA, frequency 30 Hz, pulse width 500 ms, 30 s signal on time, and 5 min signal off time; magnet-triggered current 2.0 mA and stimulation duration 60 s. The patient became seizure free 3 months after the implantation and was gradually weaned off GBP. After one year of seizure freedom, the patient voluntarily discontinued his LTG. He has remained seizure free for almost 5 years, during which time he has been gainfully employed.
Discussion
In this particular patient, an incorrect use of narrow spectrum AEDs and a history of AED noncompliance may have falsely created Vagus nerve stimulation (VNS) is generally considered as a palliative treatment for patients with drugresistant partial onset epilepsy. Although seizure freedom can be occasionally achieved in patients with VNS, anti-epileptic medications (AEDs) are commonly required to maintain seizure freedom. We report a case that a patient became seizure free for 5 years with VNS monotherapy. To our knowledge, a similar case has not been reported previously.
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the appearance of drug-resistant seizures. LTG was the only appropriate AED that was given an adequate clinical trial, albeit in combination with GBP. VPA was discontinued due to adverse effects. Perhaps monotherapy with other broad spectrum AEDs, such as levetiracetam (LEV) or torpiramate (TPM), might have been more effective, given that GGEs are often drug-responsive. 4 Regardless, this patient was reluctant to try other AEDs prior to the VNS implantation.
In general, patients with VNS rarely achieve seizure freedom. 5 Only one of 198 (0.5%) patients became seizure free in an early randomized active-control trial. 1 In more recent uncontrolled case studies, significantly higher seizure freedom rates in patients with VNS have been observed. Janszky et al. reported that 6 of 47 (13%) patients became seizure free, 6 while Ghaemi et al. reported that 10 of 144 (6.9%) patients became free of seizures. 7 Treatment with VNS earlier in the course of a seizure disorder has been associated with a greater likelihood of improvement. 8 AEDs were typically required to maintain seizure freedom in these patients. The patient in this study has been not only seizure free for 5 years, but also AED-free after VNS implantation. Although spontaneous seizure remission may occur in GGE, this is an unlikely scenario in this patient, given his history of seizures precipitated by AED noncompliance or withdrawal, as documented during long-term monitoring. Instead, we believe that his remission was achieved by VNS. We have heard of similar cases through personal communications, but they have not been formally reported in the literature. Neurostimulation is a rapidly merging treatment for drug-resistant epilepsy. Although palliative, rather than curative, the numbers of patients achieving seizure freedom are likely to increase, particularly with the addition of new techniques, including deep brain stimulation (DBS) and responsive nerve stimulation (RNS). We believe that it is clinically important to document such cases in the hope of appreciating the clinical features of patients who have the potential to become seizure free without AEDs.
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